Go Pro
NYSEAMERICAN:OSTX

OS Therapies Q4 2025 Earnings Report

OS Therapies logo
$1.90 -0.34 (-15.18%)
Closing price 04:10 PM Eastern
Extended Trading
$1.90 +0.00 (+0.05%)
As of 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

OS Therapies EPS Results

Actual EPS
-$0.41
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

OS Therapies Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

OS Therapies Announcement Details

Quarter
Q4 2025
Time
Before Market Opens
Conference Call Date
Tuesday, March 31, 2026
Conference Call Time
7:00AM ET

OS Therapies Earnings Headlines

Do this before December or regret it
Porter Stansberry believes President Trump will use the December G20 Summit in Miami to unveil a radical monetary reset tied to executive order 14241 - one he says could draw a sharp dividing line between prepared investors and those left behind. The last time America reset its money - under Nixon in the 1970s - it produced an average of 1,300 new millionaires per day for over 50 years. Stansberry's new documentary names a core group of assets he believes are positioned to surge as Trump's new dollar rolls out. Watch Porter Stansberry's full briefing and get his three steps to prepare before December.tc pixel
OS Therapies Delays Quarterly SEC Filing
See More OS Therapies Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like OS Therapies? Sign up for Earnings360's daily newsletter to receive timely earnings updates on OS Therapies and other key companies, straight to your email.

About OS Therapies

OS Therapies (NYSEAMERICAN:OSTX), a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. OS Therapies Incorporated was incorporated in 2018 and is based in Rockville, Maryland.

View OS Therapies Profile